{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ho WJ"],"funding":["Emerson Collective Cancer Research Fund","National Cancer Institute","NCI NIH HHS"],"pagination":["e000932"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7682468"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(2)"],"pubmed_abstract":["Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide with a minority of patients being diagnosed early enough for curative-intent interventions. We report the first use of preoperative cabozantinib plus nivolumab to successfully downstage what presented as unresectable HCC as part of an ongoing phase 1b study. Preoperative treatment with cabozantinib and nivolumab led to >99% reduction in alpha-fetoprotein, -37.3% radiographic reduction by RECIST 1.1 and a near complete pathologic response (80% to 100% necrosis). An integrated immunological analysis was performed on the post-treatment surgical tumor sample and matched pre-treatment and post-treatment peripheral blood samples with high-dimensional imaging and cytometry techniques. Bayesian non-negative matrix"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy."],"pmcid":["PMC7682468"],"funding_grant_id":["P30 CA006973","640183","U01 CA212007","U01 CA253403","P50 CA062924"],"pubmed_authors":["Anders R","Ho WJ","Durham J","Sharma G","Stein-O'Brien G","Popovic A","Mo G","Kamel I","Jaffee E","Fertig EJ","Zhu Q","Weiss M","Yarchoan M"],"additional_accession":[]},"is_claimable":false,"name":"Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy.","description":"Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide with a minority of patients being diagnosed early enough for curative-intent interventions. We report the first use of preoperative cabozantinib plus nivolumab to successfully downstage what presented as unresectable HCC as part of an ongoing phase 1b study. Preoperative treatment with cabozantinib and nivolumab led to >99% reduction in alpha-fetoprotein, -37.3% radiographic reduction by RECIST 1.1 and a near complete pathologic response (80% to 100% necrosis). An integrated immunological analysis was performed on the post-treatment surgical tumor sample and matched pre-treatment and post-treatment peripheral blood samples with high-dimensional imaging and cytometry techniques. Bayesian non-negative matrix","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-06-11T05:57:01.94Z","creation":"2026-06-11T03:13:15.259Z"},"accession":"S-EPMC7682468","cross_references":{"pubmed":["33219090"],"doi":["10.1136/jitc-2020-000932"]}}